SCHEMBL4890194

SCHEMBL4890194

O=C(O)c1ccc2ncnc(Nc3ccc(N4CCOCC4)cc3)c2c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.71
MAPK1 P28482 2/20 0.71
HTT P42858 2/20 0.71
AHR P35869 1/20 0.71
PI4KB Q9UBF8 1/20 0.61
CSNK2A1 P68400 1/20 0.58
TTBK1 Q5TCY1 1/20 0.55
TTBK2 Q6IQ55 1/20 0.55
NPC1 O15118 1/20 0.54
POLB P06746 1/20 0.54
RAB9A P51151 1/20 0.54
EIF2AK2 P19525 1/20 0.52
KDM4E B2RXH2 1/20 0.51
USP2 O75604 1/20 0.51
ALDH1A1 P00352 1/20 0.51
GAA P10253 2/20 0.51
LMNA P02545 1/20 0.51
MC4R P32245 1/20 0.51
CLK1 P49759 1/20 0.51
GSK3A P49840 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4888741 0.89 MAPT (0.67) MAPTMAPK1HTTAHRPI4KB
SCHEMBL4888073 0.88 MAPK1 (0.66) MAPTMAPK1HTTAHRPI4KB
SCHEMBL4891765 0.86 MAPT (0.63) MAPTMAPK1HTTAHRPI4KB
SCHEMBL4008515 0.84 MAPT (0.80) MAPTMAPK1HTTAHRPI4KB
SCHEMBL4007231 0.83 MAPT (0.78) MAPTMAPK1HTTAHRPI4KB
SCHEMBL4888050 0.83 MAPT (1.00) MAPTMAPK1HTTAHRPI4KB
SCHEMBL4886099 0.83 MAPT (0.78) MAPTMAPK1HTTAHRPI4KB
SCHEMBL14026144 0.82 MAPT (0.77) MAPTMAPK1HTTAHRPI4KB
SCHEMBL4891594 0.82 MAPT (0.77) MAPTMAPK1HTTAHRPI4KB
SCHEMBL5177220 0.81 MAPT (0.74) MAPTMAPK1HTTAHRPI4KB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080311076-A1 Morpholinylanilinoquinazoline Derivatives For Use As Antiviral Agents ARROW THERAPEUTICS LIMITED (GB) 2008-12-18 US disclosed
EP-1748991-A1 MORPHOLINYLANILINOQUINAZO- LINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS Arrow Therapeutics Limited (GB) 2007-02-07 EP disclosed
WO-2005105761-A1 MORPHOLINYLANILINOQUINAZO- LINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS ARROW THERAPEUTICS LIMITED (GB) 2005-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080311076-A1 Morpholinylanilinoquinazoline Derivatives For Use As Antiviral Agents EIF2AK2, MAVS, IRF3 MAPT 2064/4885MAPK1 1945/4885HTT 3581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.